全文获取类型
收费全文 | 13057篇 |
免费 | 849篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 157篇 |
儿科学 | 332篇 |
妇产科学 | 239篇 |
基础医学 | 1697篇 |
口腔科学 | 606篇 |
临床医学 | 1415篇 |
内科学 | 2260篇 |
皮肤病学 | 383篇 |
神经病学 | 1545篇 |
特种医学 | 449篇 |
外科学 | 1420篇 |
综合类 | 91篇 |
一般理论 | 7篇 |
预防医学 | 1374篇 |
眼科学 | 210篇 |
药学 | 887篇 |
中国医学 | 60篇 |
肿瘤学 | 819篇 |
出版年
2023年 | 73篇 |
2022年 | 119篇 |
2021年 | 246篇 |
2020年 | 167篇 |
2019年 | 239篇 |
2018年 | 278篇 |
2017年 | 217篇 |
2016年 | 297篇 |
2015年 | 350篇 |
2014年 | 407篇 |
2013年 | 580篇 |
2012年 | 868篇 |
2011年 | 1003篇 |
2010年 | 540篇 |
2009年 | 485篇 |
2008年 | 760篇 |
2007年 | 889篇 |
2006年 | 787篇 |
2005年 | 759篇 |
2004年 | 653篇 |
2003年 | 607篇 |
2002年 | 570篇 |
2001年 | 262篇 |
2000年 | 224篇 |
1999年 | 201篇 |
1998年 | 99篇 |
1997年 | 90篇 |
1996年 | 83篇 |
1995年 | 87篇 |
1994年 | 72篇 |
1993年 | 77篇 |
1992年 | 112篇 |
1991年 | 117篇 |
1990年 | 121篇 |
1989年 | 121篇 |
1988年 | 97篇 |
1987年 | 103篇 |
1986年 | 97篇 |
1985年 | 121篇 |
1984年 | 87篇 |
1983年 | 80篇 |
1982年 | 52篇 |
1981年 | 48篇 |
1979年 | 83篇 |
1978年 | 46篇 |
1977年 | 54篇 |
1976年 | 44篇 |
1974年 | 60篇 |
1973年 | 52篇 |
1972年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
A. I. Fink A. J. Jordan P. N. Lao D. A. Fong 《The British journal of ophthalmology》1988,72(4):263-269
Sixty-one patients (82 eyes) were studied after argon laser trabeculoplasty (ALT) to determine the lasting efficacy of such treatment. This investigation, now in its fourth year, was prospective, and the information derived was analysed with the aid of a computer. Success was defined as intraocular pressure (IOP) below baseline (22 mmHg). The mean follow-up time was 24.5 months, when the success rate was 74% compared with 75% at three months. Success declined to 45% at 42 months. No significant difference was noted when (a) first lasered eyes of all patients and those fellow eyes treated were analysed separately, (b) when right and left eyes were analysed separately, nor (c) when patients were divided into two treatment groups, (I) 100 burns at 1 W, and (II) 65 burns at 850 mW. Eight of 11 eyes showed progressive postlaser field loss despite below-baseline intraocular pressures. ALT is an alternative to carbonic anhydrase inhibitor therapy, with a success rate of 66.7% at two years. However, repeat ALT was successful in only 25% of patients seven months after treatment. 相似文献
72.
Regina Alber Olaf Sporns Thomas Weikert Elmar Willbold Paul G. Layer 《Anatomy and embryology》1994,190(5):429-438
Embryonic cholinesterases are assigned important functions during morphogenesis. Here we describe the expression of butyrylcholinesterase and acetylcholinesterase, and the binding of peanut agglutinin, and relate the results to mitotic activity in chick wing and leg buds from embryonic day 4 to embryonic day 9. During early stages, butyrylcholinesterase is elevated in cells under the apical ectodermal ridge and around invading motoraxons, while acetylcholinesterase is found in the chondrogenic core, on motoraxons and along the ectoderm. Peanut agglutinin binds to the apical ectodermal ridge and most prominently to the chondrogenic core. Measurements of thymidine incorporation and enzyme activities were consistent with our histological findings. Butyrylcholinesterase is concentrated near proliferative zones and periods, while acetylcholinesterase is associated with low proliferative activity. At late stages of limb development, acetylcholinesterase is concentrated in muscles and nonexistent within bones, while butyrylcholinesterase shows an inverse pattern. Thus, as in other systems, in limb formation butyrylcholinesterase is a transmitotic marker preceding differentiation, acetylcholinesterase is found on navigating axons, while peanut agglutinin appears in non-invaded regions. These data suggest roles for cholinesterases as positive regulators and peanut-agglutinin-binding proteins as negative regulators of neural differentiation. 相似文献
73.
74.
D. L. Tolbert M. Ewald J. Gutting M. C. La Regina 《The Journal of comparative neurology》1995,355(4):490-507
Temporal-spatial patterns of surviving Purkinje cells were studied quantitatively in a rat mutant (shaker) with differential hereditary cerebellar ataxia and Purkinje cell degeneration. Shaker rat mutants are characterized behaviorally as mild if they are ataxic or as strong if they have ataxia and tremor. Purkinje cells degenerate in both mild and strong shaker mutants, but the temporal and spatial patterns of cell death are strikingly different. In mild shaker mutants, Purkinje cell death is temporally restricted, with 31-46% of the Purkinje cells in lobules I-IX dying by 3 months of age. Very few Purkinje cells degenerate after this age. Purkinje cell death is spatially random. In lobules I-IX, every second, third, or fourth Purkinje cell degenerates. Purkinje cells in lobule X do not degenerate. In strong shaker mutants, Purkinje cell degeneration is temporally protracted and spatially restricted. By 3 months of age, most Purkinje cells in lobules I-VIa, -b, and -d, and -d have degenerated. Numerous Purkinje cells in the paravermis of lobules VIIb-VIII have also degenerated. Surviving Purkinje cells in the vermis and lateral hemisphere of lobules VIIb-VIII are aligned in parasagittally oriented stripes or transversely oriented bands. Purkinje cells continue to degenerate in localized areas of the posterior lobe such that, by 18 months of age, surviving Purkinje cells are limited primarily to lobules VIc, VIIa, IXd, and X. Quantitative analysis indicates that none of the Purkinje cells in these lobules degenerate. 相似文献
75.
Aberrant epididymal tissue: a significant clinical entity 总被引:1,自引:0,他引:1
76.
In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. 总被引:6,自引:0,他引:6
Munmun Chattopadhyay Darren Wolfe Shaohua Huang James Goss Joseph C Glorioso Marina Mata David J Fink 《Annals of neurology》2002,51(1):19-27
Neurotrophic factors have been demonstrated to prevent the development of peripheral neuropathy in animal models, but the therapeutic use of these factors in human disease has been limited by the short serum half-life and dose-limiting side effects of these potent peptides. We used peripheral subcutaneous inoculation with a replication-incompetent, genomic herpes simplex virus-based vector containing the coding sequence for neurotrophin-3 to transduce sensory neurons of the rat dorsal root ganglion in vivo, and found that expression of neurotrophin-3 from the vector protected peripheral sensory axons from neuropathy induced by intoxication with pyridoxine assessed by electrophysiological (foot sensory response amplitude, and conduction velocity, and H-wave), histological (nerve morphology and morphometry), and behavioral measures of proprioceptive function. In vivo gene transfer using herpes simplex virus vectors provides a unique option for treatment of diseases of the sensory peripheral nervous system. 相似文献
77.
78.
Wagner Jurgen; Madry Henning; Reszka Regina 《Nephrology, dialysis, transplantation》1995,10(10):1801-1807
Renal gene transfer techniques are being developed as a novelexperimental approach to understand the pathogenesis of renaldisease and to potentially develop new therapeutic tools. Wereview the currently available technology to introduce foreigngenetic material into renal tissue, i.e., retroviral, adenoviral,and liposomal transfer systems with their respective advantagesand caveats. Today, the transfer efficiency of these methodsappears to be sufficiently high to study the effects of transducedgenes on renal function and morphology in rat kidney. This willallow (i) the elucidation of the function of genes on the courseof renal disease in experimental animal models and (ii) themodulation of local expression of endogenous genes which presumptivelycontribute to renal pathology in these models. One strategyto accomplish this aim is the use of recombinant DNA technologyto design antisense DNA constructs or oligonucleotides, whichinterfere with the renal expression of target genes. We willalso discuss some of the shortcomings of the currently usedtechniques with respect to potential therapeutic use of genetransfer systems and gene modulation. 相似文献
79.
80.
Michael Fromm Wolfgang E. Berdel Hans D. Schick Susanne Danhauser-Riedl Ulrich Fink Wolfgang Remy Anneliese Reichert Anke Ankele Heinz W. Präuer Jörg R. Siewert Johann Rastetter 《Investigational new drugs》1988,6(3):189-194
Summary Carbetimer, a new synthetic low molecular weight polyelectrolyte with a novel structure displayed antitumor activiy in a number of animal tumor model systems and in vitro investigations. Based on these findings it was brought to a phase I clinical trial in patients with advanced malignant disease after failure of conventional treatment or with no conventional treatment available. Forty-eight patients received 98 courses. The schedule was a one hour i.v. infusion every four weeks. The starting dose was 180 mg/m2 and dose escalation was performed according to a modified Fibonacci formula up to 16,690 mg/m2. At least three patients were treated at each dose level and each patient was eligible to receive repeat courses at the same dose, until progressive disease or dose-limiting toxicity intervened. No hematological toxicity was encountered. Some adverse effects such as reversible proteinuria, hypercalcaemia, pain at infusion site, nausea and vomiting and fatigue were seen partly in a dose-related manner but did not represent the maximum tolerated dose (MTD). The limiting toxicity at the highest dose level of 16,690 mg/m2 consisted of ocular symptoms (light flashes) accompanied by a modest decrease of blood pressure and nausea or vomiting during a one hour infusion. 16,690 mg/m2/1 hour was considered the MTD. There were four deaths on study, all considered diseaserelated. Fourteen patients had stable disease for more than two courses, which, however, could also be explained by the natural course of disease. No clear-cut antitumor responses were noted in our study center.The recommended dose for phase II trials derived from our results is 12,550 mg/m2/2 hours. However, with regard to experiences in other phase I studies, the subsequent phase II studies will be performed with a dose of 6,500 mg/m2. 相似文献